Hostname: page-component-89b8bd64d-dvtzq Total loading time: 0 Render date: 2026-05-06T08:23:21.381Z Has data issue: false hasContentIssue false

Evaluation of ALS-resistant yellow nutsedge (Cyperus esculentus) in Georgia peanut

Published online by Cambridge University Press:  30 October 2024

Hannah C. Lindell
Affiliation:
Graduate Research Assistant, Department of Crop and Soil Sciences, University of Georgia, Athens, GA, USA
Eric P. Prostko
Affiliation:
Professor and Extension Weed Specialist, Department of Crop and Soil Sciences, University of Georgia, Tifton, GA, USA
Scott McElroy
Affiliation:
Professor in Weed Science and Turf, Department of Crop, Soil and Environmental Sciences, Auburn University, Auburn, AL, USA
Jinesh D. Patel
Affiliation:
Research Associate, Department of Crop, Soil and Environmental Sciences, Auburn University, Auburn, AL, USA
Jason D. Blankenship
Affiliation:
Former Randolph County Extension Agent, University of Georgia Cooperative Extension, Cuthbert, GA, USA
Timothy L. Grey
Affiliation:
Professor, Department of Crop and Soil Sciences, University of Georgia, Tifton GA, USA
Nicholas T. Basinger*
Affiliation:
Associate Professor, Department of Crop and Soil Sciences, University of Georgia, Athens, GA, USA
*
Corresponding author: Nicholas T. Basinger; Email: Nicholas.basinger@uga.edu
Rights & Permissions [Opens in a new window]

Abstract

Accounting for 53% of U.S. peanuts (Arachis hypogaea L.), Georgia is the top peanut-producing state, with approximately 1.42 billion kg produced in 2023. Peanut producers often use the acetolactate synthase (ALS) imidazolinone herbicide imazapic, but reduced yellow nutsedge (Cyperus esculentus L.) control was reported in Georgia peanuts after 4 yr of continuous imazapic use. This study aimed to determine the level of resistance (LD50, I50, and GR50) and potential cross-resistance for the suspected resistant population and to identify the associated genetic mutations conferring resistance. A susceptible biotype was treated with 0, 0.0088, 0.0175, 0.035, 0.07, 0.14, 0.28, and 0.56 kg ai ha−1, and a resistant biotype was sprayed with 0, 0.07, 0.14, 0.28, 0.56, 1.13, 2.26, and 4.5 kg ai ha−1 of imazapic. To determine whether the suspected resistant biotype was cross-resistant to halosulfuron-methyl, an ALS herbicide used to control Cyperus spp., both biotypes were treated with 0, 0.0117, 0.0233, 0.0466, 0.0933, 0.187, 0.373, and 0.746 g ai ha−1 of halosulfuron-methyl. Plants were rated for injury at 7, 14, and 28 d after treatment (DAT), and aboveground biomass was harvested at 28 DAT. For imazapic, LD50 was 0.041 and 1.503 kg ai ha−1 and the GR50 was estimated to be 0.0128 and 1.853 kg ha−1 for Sus and Res biotypes, respectively, indicating 36- and 145-fold increase in resistance of the Res biotype for I50 and GR50, respectively. Both biotypes responded similarly to applications of halosulfuron-methyl, with biomass reduction at rates greater than 0.023 kg ai ha−1. Transcriptome profiles revealed a mutation in the target-site gene of the resistant biotype causing an amino acid substitution from alanine to valine at position 205 (Ala-205-Val). Growers should continue to rotate chemistries and implement integrated weed management approaches for control of C. esculentus, as the use of imazapic over consecutive years has led to resistance in C. esculentus.

Information

Type
Research Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of Weed Science Society of America
Figure 0

Figure 1. Size comparison of Cyperus esculentus tubers (left) and peanut seeds (right).

Figure 1

Table 1. Herbicide dose of imazapic and halosulfuron-methyl to determine I50 and GR50 of suspected acetolactate synthase (ALS)-resistant Cyperus esculentusa.

Figure 2

Figure 2. Injury of suspected resistant and known susceptible Cyperus esculentus in response to imazapic applications.

Figure 3

Figure 3. Response of known susceptible Cyperus esculentus (A) and suspected resistant C. esculentus (at 28 DAT) to applications of imazapic (B). Numbers indicate imazapic rate (kg ai ha−1).

Figure 4

Figure 4. Biomass response of suspected resistant and known susceptible Cyperus esculentus to imazapic applications.

Figure 5

Figure 5. Mortality response of suspected resistant and known susceptible Cyperus esculentus to imazapic applications.

Figure 6

Figure 6. Biomass response of suspected resistant and known susceptible Cyperus esculentus to halosulfuron-methyl applications.

Figure 7

Table 2. Missense mutations were identified in both susceptible and resistant Cyperus esculentus in the transcriptome data.

Figure 8

Figure 7. Alignment of Illumina sequencing reads from susceptible (Sus) biotype (A) and resistant (Res) biotype (B) of Cyperus esculentus to acetolactate synthase (ALS) gene from Cyperus difformis (GenBank accession no. EF061294.2) focusing on target-site mutation Ala-205-Val. The horizontal line color codes highlight mismatches in the nucleotide sequences of mapped reads compared with the reference sequence: red for adenine (A), blue for cytosine (C), yellow for guanine (G), and green for thymine (T).

Figure 9

Table 3. Mutations exclusively found in transcriptome data of resistant biotype of Cyperus esculentus.